5.40

1.46% -0.08

Cumberland Pharmaceuticals Inc (CPIX)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Cumberland Pharmaceuticals Inc stock is traded at $5.40, with a volume of 25,771. It is down -1.46% in the last 24 hours and up +14.65% over the past month. Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.

Previous Close:

$5.48

Open:

$5.36

24h Volume:

25,771

Relative Volume:

0.66

Market Cap:

$82.44M

Revenue:

$37.79M

Net Income/Loss:

$-10.38M

P/E Ratio:

-7.3973

EPS:

-0.73

Net Cash Flow:

$-1.00M

1W Performance:

-2.00%

1M Performance:

+14.65%

6M Performance:

+154.72%

1Y Performance:

+262.42%

1-Day Range:

$5.36

$5.615

1-Week Range:

$5.1142

$5.88

52-Week Range:

$1.04

$7.25

Cumberland Pharmaceuticals Inc Stock (CPIX) Company Profile

Name

Cumberland Pharmaceuticals Inc

Sector

Healthcare (1172)

Industry

Drug Manufacturers - Specialty & Generic (82)

Phone

615-255-0068

Address

2525 WEST END AVENUE, NASHVILLE,, TN

Employee

Twitter

Next Earnings Date

2025-03-04

Latest SEC Filings

CPIX's Discussions on Twitter

Compare CPIX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CPIX Cumberland Pharmaceuticals Inc	5.40	82.44M	37.79M	-10.38M	-1.00M	-0.73
RGC Regencell Bioscience Holdings Ltd	78.00	303.95B	0	-5.87M	-767.30K	-0.45
ZTS Zoetis Inc	161.67	74.39B	9.29B	2.52B	2.28B	5.57
HLN Haleon Plc Adr	10.50	48.97B	14.35B	1.85B	0	0.4023
TAK Takeda Pharmaceutical Co Adr	14.89	47.60B	30.08B	710.16M	4.45B	0.2182
TEVA Teva Pharmaceutical Industries Ltd Adr	16.89	20.17B	16.54B	-1.64B	749.00M	-1.45

Cumberland Pharmaceuticals Inc Stock (CPIX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-12-12	Reiterated	UBS	Neutral
Feb-01-11	Reiterated	UBS	Neutral
Dec-16-10	Downgrade	UBS	Buy → Neutral
Aug-17-10	Downgrade	Jefferies	Buy → Hold
Aug-17-10	Reiterated	Morgan Joseph	Buy
Aug-17-10	Reiterated	UBS	Buy
May-14-10	Reiterated	Morgan Joseph	Buy

View All

Cumberland Pharmaceuticals Inc Stock (CPIX) Latest News

Jun 17, 2025

Asthma Market to Expand Significantly by 2034, States - openPR.com

Jun 17, 2025

Asthma Market to Expand Significantly by 2034, States DelveInsight Report | GSK, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma, Genentech - Barchart.com

Jun 17, 2025

Jun 14, 2025

Two Sigma Investments LP Has $89,000 Stake in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) - Defense World

Jun 14, 2025

Jun 12, 2025

Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Cross Above Two Hundred Day Moving Average – Here’s Why - Defense World

Jun 12, 2025

Jun 06, 2025

Cumberland pharmaceuticals director Kenneth Krogulski acquires $4,824 in stock By Investing.com - Investing.com South Africa

Jun 06, 2025

Cumberland pharmaceuticals director Kenneth Krogulski acquires $4,824 in stock - Investing.com

Jun 06, 2025

Jun 05, 2025

Dilated Cardiomyopathy Market Witnesses Robust Growth During the Study Period (2020–2034) Amid Advancements in Cardiovascular Therapies | DelveInsight - GlobeNewswire Inc.

Jun 05, 2025

Jun 04, 2025

Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Passes Above 200 Day Moving Average – Time to Sell? - Defense World

Jun 04, 2025

Jun 02, 2025

Investors in Cumberland Pharmaceuticals (NASDAQ:CPIX) have seen splendid returns of 235% over the past year - Yahoo

Jun 02, 2025

May 27, 2025

NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS - PR Newswire

May 27, 2025

Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Passes Above Two Hundred Day Moving Average – Here’s Why - Defense World

May 27, 2025

May 22, 2025

Q&A: Cumberland Pharmaceuticals CEO A.J. Kazimi weighs in on industry challenges, strengths - The Business Journals

May 22, 2025

May 21, 2025

Cumberland CEO A.J. Kazimi: Pharmaceutical tariffs would be 'concerning' - The Business Journals

May 21, 2025

May 17, 2025

Dimensional Fund Advisors LP Cuts Stock Position in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) - Defense World

May 17, 2025

May 14, 2025

Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025 - The Victoria Advocate

May 14, 2025

May 13, 2025

Cumberland, Qureight Collaborate on Lung Disease Treatment Trial - marketscreener.com

May 13, 2025

CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH - PR Newswire

May 13, 2025

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 13, 2025

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Held Back By Insufficient Growth Even After Shares Climb 30% - simplywall.st

May 13, 2025

Cumberland Pharmaceuticals Leverages AI Technology to Transform IPF Treatment Research in Major Clinical Trial - Stock Titan

May 13, 2025

May 12, 2025

Cumberland Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks

May 12, 2025

May 10, 2025

Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Rating Upgraded by StockNews.com - Defense World

May 10, 2025

May 07, 2025

Cumberland Pharmaceuticals Reports Strong Q1 2025 Growth - TipRanks

May 07, 2025